Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

The Prognostic Value of Lymphovascular Invasion in Combination with Nodal Stage on Disease-specific Survival in Patients with Bladder Cancer Following Upfront Radical Cystectomy.

European urology focus·2026

Stromal innervation is prognostic in non-muscle-invasive bladder cancer and predicted by a distinct microenvironmental transcriptomic signature.

bioRxiv : the preprint server for biology·2026

Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer.

European urology open science·2026

X and Y chromosomes as determinants of aging and disease.

Science (New York, N.Y.)·2026

Recurrent deletions and regulatory disruption of the Y chromosome in cancer.

Communications biology·2026

Human Y chromosome pan-organ mapping reveals progressive mosaic loss from normal to cancer.

JCI insight·2026

Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference.

European urology·2026

Epidemiology, Risk Factors, and Prevention of Prostate Cancer.

European urology·2026

Surgery in Motion: Different Surgical Techniques for Inguinal Lymph Node Dissection in Penile Cancer.

European urology·2026

Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10 yr.

European urology·2026

177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial.

European urology·2026

Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial.

European urology·2026

Predicting recurrence risk after neoadjuvant therapy in breast cancer: a single-center retrospective cohort study integrating residual cancer burden and immune microenvironment features.

Frontiers in oncology·2026

Prognostic associations of PD-L1 expression and BAP1 loss in pleural mesothelioma: a retrospective single-center cohort from Colombia.

Frontiers in oncology·2026

Multiparametric MRI radiomics for preoperative prediction of tumor budding grade in rectal cancer.

Frontiers in oncology·2026

IVIM-based habitat imaging for non-invasive assessment of Ki-67 proliferation status in cervical cancer.

Frontiers in oncology·2026

Diagnostic performance of next-generation sequencing in thyroid nodules and molecular correlates of tumor aggressiveness in papillary thyroid carcinoma.

Frontiers in endocrinology·2026

Multimodal radiomics based on dynamic contrast-enhanced ultrasound for predicting cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis.

Frontiers in oncology·2026

Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

Related Experiment Videos

Related Concept Videos

The Prognostic Value of Lymphovascular Invasion in Combination with Nodal Stage on Disease-specific Survival in Patients with Bladder Cancer Following Upfront Radical Cystectomy.

Stromal innervation is prognostic in non-muscle-invasive bladder cancer and predicted by a distinct microenvironmental transcriptomic signature.

Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer.

X and Y chromosomes as determinants of aging and disease.

Recurrent deletions and regulatory disruption of the Y chromosome in cancer.

Human Y chromosome pan-organ mapping reveals progressive mosaic loss from normal to cancer.

Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference.

Epidemiology, Risk Factors, and Prevention of Prostate Cancer.

Surgery in Motion: Different Surgical Techniques for Inguinal Lymph Node Dissection in Penile Cancer.

Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10 yr.

177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial.

Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial.

Predicting recurrence risk after neoadjuvant therapy in breast cancer: a single-center retrospective cohort study integrating residual cancer burden and immune microenvironment features.

Prognostic associations of PD-L1 expression and BAP1 loss in pleural mesothelioma: a retrospective single-center cohort from Colombia.

Multiparametric MRI radiomics for preoperative prediction of tumor budding grade in rectal cancer.

IVIM-based habitat imaging for non-invasive assessment of Ki-67 proliferation status in cervical cancer.

Diagnostic performance of next-generation sequencing in thyroid nodules and molecular correlates of tumor aggressiveness in papillary thyroid carcinoma.

Multimodal radiomics based on dynamic contrast-enhanced ultrasound for predicting cervical lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis.

Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy

Related Experiment Videos

Related Concept Videos

Related Articles